ATE453718T1 - Verfahren zur verbesserung von krebstherapie - Google Patents
Verfahren zur verbesserung von krebstherapieInfo
- Publication number
- ATE453718T1 ATE453718T1 AT05023231T AT05023231T ATE453718T1 AT E453718 T1 ATE453718 T1 AT E453718T1 AT 05023231 T AT05023231 T AT 05023231T AT 05023231 T AT05023231 T AT 05023231T AT E453718 T1 ATE453718 T1 AT E453718T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer therapy
- treatment
- improving cancer
- methods
- retinoids
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000011275 oncology therapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 230000001594 aberrant effect Effects 0.000 abstract 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 229930002330 retinoic acid Natural products 0.000 abstract 1
- 150000004492 retinoid derivatives Chemical class 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 229960001727 tretinoin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22891400P | 2000-08-29 | 2000-08-29 | |
US09/759,056 US7173115B2 (en) | 2000-01-13 | 2001-01-11 | Stra6 polypeptides |
US09/901,812 US20020173461A1 (en) | 2000-01-13 | 2001-07-10 | Methods for enhancing the efficacy of cancer therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE453718T1 true ATE453718T1 (de) | 2010-01-15 |
Family
ID=27397886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05023231T ATE453718T1 (de) | 2000-08-29 | 2001-07-10 | Verfahren zur verbesserung von krebstherapie |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP1666600B1 (de) |
JP (1) | JP2004507251A (de) |
KR (1) | KR20080068147A (de) |
AT (1) | ATE453718T1 (de) |
AU (1) | AU2001271938A1 (de) |
CA (1) | CA2420867C (de) |
DE (1) | DE60140966D1 (de) |
ES (1) | ES2337696T3 (de) |
NZ (1) | NZ524230A (de) |
WO (1) | WO2002018608A2 (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030021788A1 (en) * | 2000-03-23 | 2003-01-30 | Diane Pennica | Novel human STRA6-like protein and nucleic acids encoding the same |
CA2481239A1 (en) * | 2002-04-05 | 2003-10-23 | University Of Utah Research Foundation | Regulation of a novel colon specific retinol dehydrogenase by apc and cdx2 |
CA2483449A1 (en) | 2002-04-25 | 2003-11-06 | University Of Connecticut Health Center | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
EP2290087A3 (de) * | 2004-12-22 | 2011-06-15 | Genentech, Inc. | Verfahren zur Herstellung von Löslichen Multi-Membranproteinen |
TWI407971B (zh) * | 2007-03-30 | 2013-09-11 | Nitto Denko Corp | Cancer cells and tumor-related fibroblasts |
MY175338A (en) | 2011-05-16 | 2020-06-19 | Genentech Inc | Fgfr1 agonists and methods of use |
TWI670283B (zh) | 2013-12-23 | 2019-09-01 | 美商建南德克公司 | 抗體及使用方法 |
CN114574378B (zh) * | 2022-04-11 | 2023-09-22 | 浙江大学 | 一种生产视黄酸的基因工程菌及其构建方法和应用 |
CN117625626B (zh) * | 2024-01-25 | 2024-04-16 | 中国农业科学院植物保护研究所 | RNAi在提高苏云金芽胞杆菌杀虫蛋白防治二化螟或草地贪夜蛾效果中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4997852A (en) * | 1987-08-26 | 1991-03-05 | Ohio State University Research Foundation | Method and composition for achieving cancer chemopreventive and chemotherapeutic activity |
US5731167A (en) * | 1992-01-17 | 1998-03-24 | The United States Of America As Represented By The Department Of Health And Human Services | Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy |
AU2582897A (en) | 1996-03-15 | 1997-10-01 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
NZ520095A (en) * | 2000-01-13 | 2004-05-28 | Genentech Inc | Novel Stra6 polypeptides, nucleic acids, antibodies, compositions and methods of treatments for inhibiting tumor cell growth |
-
2001
- 2001-07-10 NZ NZ524230A patent/NZ524230A/en not_active IP Right Cessation
- 2001-07-10 AU AU2001271938A patent/AU2001271938A1/en not_active Abandoned
- 2001-07-10 JP JP2002522514A patent/JP2004507251A/ja active Pending
- 2001-07-10 WO PCT/US2001/021635 patent/WO2002018608A2/en not_active Application Discontinuation
- 2001-07-10 AT AT05023231T patent/ATE453718T1/de not_active IP Right Cessation
- 2001-07-10 ES ES05023231T patent/ES2337696T3/es not_active Expired - Lifetime
- 2001-07-10 EP EP05023231A patent/EP1666600B1/de not_active Expired - Lifetime
- 2001-07-10 KR KR1020087015948A patent/KR20080068147A/ko not_active Application Discontinuation
- 2001-07-10 EP EP01950996A patent/EP1341923A2/de not_active Withdrawn
- 2001-07-10 CA CA2420867A patent/CA2420867C/en not_active Expired - Fee Related
- 2001-07-10 DE DE60140966T patent/DE60140966D1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE60140966D1 (de) | 2010-02-11 |
WO2002018608A2 (en) | 2002-03-07 |
JP2004507251A (ja) | 2004-03-11 |
WO2002018608A9 (en) | 2003-08-07 |
KR20080068147A (ko) | 2008-07-22 |
EP1341923A2 (de) | 2003-09-10 |
WO2002018608A3 (en) | 2003-06-26 |
EP1666600B1 (de) | 2009-12-30 |
NZ524230A (en) | 2006-05-26 |
EP1666600A1 (de) | 2006-06-07 |
AU2001271938A1 (en) | 2002-03-13 |
CA2420867A1 (en) | 2002-03-07 |
ES2337696T3 (es) | 2010-04-28 |
CA2420867C (en) | 2013-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE411399T1 (de) | Behandlung der huntington's krankheit mit epa | |
ATE519862T1 (de) | Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von gebärmutterhalskrebs | |
DE60032795D1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
ATE540129T1 (de) | Target zur therapie kognitiver behinderungen | |
CR9512A (es) | Metodos para el tratamiento de tumores de cerebro con anticuerpos | |
WO2003004989A3 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer | |
DE60020529D1 (de) | Antikörper zur krebsbehandlung und -diagnose | |
ATE299860T1 (de) | Vebindungen zur modulation des rage-rezeptors | |
ATE444967T1 (de) | Spezifische bindungsmittel von human angiopoietin-2 | |
CY1108960T1 (el) | Αντισωματα αποκλεισμου cripto και οι χρησεις τους | |
WO2004050707A3 (de) | Tumorspezifische erkennungsmoleküle | |
ATE453718T1 (de) | Verfahren zur verbesserung von krebstherapie | |
WO2004106495A3 (en) | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer | |
BR0306715A (pt) | Métodos para diagnóstico e tratamento de tumores | |
ATE319439T1 (de) | Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd | |
ATE531813T1 (de) | System zur überwachung einer bakteriellen tumorbehandlung | |
DE60218843D1 (de) | Verfahren zur identifizierung von mitteln zur behandlung von diabetes | |
NO20054631L (no) | Antistoff mot tumorspesifikt antigen som mal | |
DE60124526D1 (de) | Methode zur identifizierung von helicobacter antigenen | |
NO20002412D0 (no) | FremgangsmÕte for behandling av tumorer og tumorceller ved anvendelse av ex vivo aktiverte T celler | |
ATE403864T1 (de) | Verfahren zur identifizierung von substanzen, die die aktivität von hyperpolarisations-aktivierten kationen-kanälen modulieren | |
DE60140074D1 (de) | Non-apoptotische formen des zelltods und verfahren zur modulation | |
ES2502366T3 (es) | Inducción de inmunidad tumoral por variantes de proteína de unión a folato | |
DE69932922D1 (de) | Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen | |
DE60111620D1 (de) | Aktiviertes protein c zur behandlung von pankreatitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |